This trial is active, not recruiting.

Condition cystic fibrosis
Sponsor Haukeland University Hospital
Collaborator University of Bergen
Start date January 2011
End date July 2018
Trial size 60 participants
Trial identifier NCT01446861, 2010/2857-7


Purpose The purpose of this study is to develop and validate multimodal testing of exocrine pancreatic function (EPF). The investigators will be testing exocrine pancreatic function in patients with cystic fibrosis (CF). Exocrine pancreatic function and imaging will be correlated to age group, genotype, nutritional status and quality of life. Earlier detection of exocrine pancreatic failure in the non classical form of cystic fibrosis may be of therapeutically benefit.

Hypotheses Endoscopic short test can be applied in diagnosing and monitoring exocrine pancreatic function in patients with cystic fibrosis.

New functional testing of exocrine pancreatic function is superior to traditional testing with fecal elastase.

MRI and ultrasound methods can give volume output estimate in cystic fibrosis patients.

Contrast enhanced ultrasound can quantify reduced or delayed pancreatic perfusion and parenchymal changes in cystic fibrosis patients.

Elastography/ CEUS can be used in prediction and monitoring of fibrosis development and development of hepatocellular carcinoma in the liver of cystic fibrosis patients.

Immunohistochemical quantification of secretin/ cholecystokinin (CCK) producing cell in duodenum can be utilized as a model hormonal signaling in cystic fibrosis patients with exocrine pancreatic function.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective cross-sectional
Consecutive cystic fibrosis patients attending regular Controls at the CF clinic in Bergen
Age and gender matchet healthy Controls recruited by Board notice and advertising.

Primary Outcomes

peak lipase IE
time frame: one year

Secondary Outcomes

enzyme production
time frame: 2 years

Eligibility Criteria

Male or female participants at least 15 years old.

Inclusion Criteria: - Diagnosis cystic fibrosis. Age over 15 years. Assigned to routine control at department of lung diseases, Haukeland university hospital. Exclusion Criteria: - Unable to concent, allergies to Sonovue ultrasound contrast, pregnant or breastfeeding, contraindications against endoscopy.

Additional Information

Official title Pancreatic Failure in Patients With Cystic Fibrosis A Multimodal Study of Exocrine Pancreatic Failure in Cystic Fibrosis
Principal investigator Georg Dimcevski, MD, PhD
Description Study design: Observational, cohort studies. Patient characterization: Age, gender, and Genetic status from electronical records. Exocrine function testing (EPF): Secretin stimulated ultrasound and short endoscopic secretin test (EST). Faecal Elastase. Imaging: Transabdominal ultrasound of the liver and pancreas. secretin stimulated MRI. Contrast enhanced ultrasound (CEUS) of the pancreas using SonoVue contrast. Endpoints: Study 1: Exocrine pancreatic function by duodenal bicarbonate/ Enzymes related to Genetics and F elastase. Study 2: Ultrasound parenchymal changes of the pancreas related to Genetics and EPF. Study 3/4: Pancreatic secretion by ultrasound, MRI and EST related to EPF Study 5; Perfusion of the pancreas by CEUS related to EPF Study 6: Genotype-phenotype conciderations of the CF pancreas.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Haukeland University Hospital.